Short answer
Tonix Pharmaceuticals Holding Corp. (TNXP) filed an 8-K current report with the SEC on November 13, 2026 reporting Item 8.01 (Other Events). DRL filed a Paragraph IV ANDA challenging four Orange Book patents covering TONMYA 2.8 mg.
Tonix Pharmaceuticals Holding Corp. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- DRL filed a Paragraph IV ANDA challenging four Orange Book patents covering TONMYA 2.8 mg
- Tonix sued DRL for patent infringement in New Jersey on November 13, 2026
- Lawsuit triggers up to 30-month statutory stay of final FDA approval for DRL’s generic
- Patent litigation protects TONMYA exclusivity temporarily but creates legal costs and generic-competition risk
- Adverse patent ruling could accelerate generic entry and pressure TONMYA sales
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tonix Pharmaceuticals Holding Corp. 8-K filings
Get the next TNXP 8-K as it lands
Follow TNXP for push alerts, or ask the research agent what this filing means.